Login to Your Account



Bioarctic and Eisai target protofibrils in Alzheimer’s disease

By Cormac Sheridan
Staff Writer

Tuesday, March 4, 2014
STOCKHOLM – The vexed problem of conclusively proving – or disproving – the amyloid hypothesis as the key driver of the pathology of Alzheimer’s disease has been exhaustively rehearsed in multiple settings over the last decade.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription